Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial

A randomized controlled trial in Ethiopia comparing the efficacy and safety of primaquine regimens for radical cure.

Author: , , , , , , , , , , , , , , , , , , , , , , , , , ,
Publication date: May 2017
Source: PLOS Medicine

Development of a pharmacovigilance safety monitoring tool for the rollout of single low-dose primaquine and artemether-lumefantrine to treat Plasmodium falciparum infections in Swaziland: a pilot study

Improved pharmacovigilance to monitor and promote the safety of the WHO recommendation is needed. The successful application of the Primaquine Roll Out Monitoring Pharmacovigilance Tool (PROMPT) demonstrates its potential as an important tool to rapidly generate locally acquired safety data and support pharmacovigilance in resource-limited settings.

Author: , , , , , , , , , , , , , , , ,
Publication date: July 2016
Source: Malaria Journal

Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomised phase 2 trial

Single low doses of primaquine, when added to artemisinin-based combination therapy, might prevent transmission of Plasmodium falciparum malaria to mosquitoes. A single dose of 0·25 mg/kg primaquine, given alongside dihydroartemisinin–piperaquine, was safe and efficacious for the prevention of P falciparum malaria transmission in boys and men who are not deficient in G6PD

Author: , , , , , , , , , , , , , , , , , , ,
Publication date: June 2016
Source: The Lancet Infectious Diseases

An assessment of the supply, programmatic use, and regulatory issues of single low-dose primaquine as a Plasmodium falciparum gametocytocide for sub-Saharan Africa.

This article outlines some of the barriers to single low-dose (SLD) primaquine use to stop P. falciparum transmission. In-country key informants revealed that the WHO weight-based recommendation to use SLD primaquine is challenging to implement in actual field settings, due in part to safety concerns involving G6PD deficiency and drug-drug interactions, among other factors.

Author: , , , , , , , ,
Publication date: May 2015
Source: Malaria Journal

Review of Mass Drug Administration for Malaria and Its Operational Challenges

Despite some substantial knowledge gaps, MDA has been used successfully to control and eliminate Plasmodium falciparum and P. vivax malaria in the past, and should be considered as part of a comprehensive malaria elimination strategy in aspecific settings.

Author: , , , , , , , , , , , ,
Publication date: May 2015
Source: AJTMH

The challenge of artemisinin resistance can only be met by eliminating Plasmodium falciparum malaria across the Greater Mekong subregion

Foci of artemisinin drug resistance have been identified in the Greater Mekong subregion (GMS) of the Asia Pacific, threatening the major gains made in malaria control and potentially creating a parasite pool that is more difficult to treat and eliminate. … A sustainable solution is the rapid elimination of all Plasmodium falciparum parasites from the GMS.

Author: , , , , , , ,
Publication date: July 2014
Source: Malaria Journal

Rationale for short course primaquine in Africa to interrupt malaria transmission

A report of a meeting held in London in March 2012, discussing the existing evidence on the ability of primaquine to block malaria transmission, defining the roadblocks to the use of primaquine in Africa and to developing a roadmap to enable its rapid, safe and effective deployment.

Author: , ,
Publication date: October 2012
Source: Malaria Journal